Health ❯ Healthcare ❯ Pharmaceuticals ❯ Cancer Treatment

Bladder Cancer

ImmunityBio Rallies as Anktiva Sales Surge 700% and Registrational Trial Passes 85% Enrollment

The company now reports its NMIBC registrational study is more than 85% enrolled, targeting a late-2026 FDA filing.

FDA Approves Perioperative Keytruda–Padcev for Cisplatin‑Ineligible Muscle‑Invasive Bladder Cancer

FDA Approves J&J’s Inlexzo Bladder Drug-Delivery Device for BCG‑Unresponsive NMIBC